Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AVXL - 2-73 - Just what I needed.
Agree. With the information we know today on all drug trial results this company should have a $5 to $10 billion market cap. Diagnosis! Market corruption. imo
Lol. Great to hear from you, Xena.
Right! Makes you wonder who he's working for.
Reminiscences of a Retail Stock Investor: The Naked Short. They were here protesting the injustice of manipulative and deceptive trading practices, including naked shorting. These practices are just the tip of an iceberg for a broader systemic problem facing a corrupted financial services industry, and had impacted every person in the room.
https://westviewnews.org/2023/02/23/reminiscences-of-a-retail-stock-investor-the-naked-short/james/
Shake it up group ... with all you got.
The Cars.
Exaggerated effort to keep stock price down so retail can't make any money.
Posted by ChartMill on ST. ANAVEX LIFE SCIENCES CORP (AVXL) Analysts have set a mean price target of 45.29. This target is 328.05% above the current price.
https://www.chartmill.com/stock/quote/AVXL/analyst-ratings
Hoth Therapeutics Shares Rise After Firm Hired to Investigate Alleged Naked Shorting Activity
https://www.marketwatch.com/story/hoth-therapeutics-shares-rise-after-firm-hired-to-investigate-alleged-naked-shorting-activity-13548201
Nice post, T. We need block chain share trading to remove naked shorting. Account for each share traded in all stocks.
Nobody is buying the candy he is selling anymore. To much evidence that 2-73 is best in CNS class.
Bravo, georgejjl. Good post. Imo - That patent is probably worth $10 to $15 billion in early application. Nice!
AVXL- Best in class in the CNS biotech space.
"We are excited with the continued advancement of our lead product candidate ANAVEX 2-73 in Alzheimer disease and Rett syndrome as we maintain our attention on execution across each of our clinical programs, and overall business operations. We were very pleased to present top line data of the randomized double-blind placebo controlled Phase 2b/3 study for the treatment of early Alzheimer disease at the CTAD Congress 2022 on December 1. The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints".
Anavex Life Sciences Stock Shows Improved Price Strength Rating
https://www.investors.com/news/technology/anavex-life-sciences-stock-hows-improved-price-strength-rating/?src=A00220
Never mind. Found it. Thanks
https://www.nasdaq.com/market-activity/stocks/avxl/institutional-holdings
What is the current percentage of institutional ownership? TIA
Saturday night Special.
Band off Brothers.
What I would like to see: AVXL Blarcamazine A2-73 approved in the E.U. BP company offers $4.0 billion up front and 30% stake in profits. AVXL opens at $75.50 per share.
That is what I would like to see, Nidan.:)
Anavex gains as trial for Rett syndrome candidate exceeds enrollment target.
https://seekingalpha.com/news/3931220-avxl-stock-gains-rett-syndrome-trial-exceeds-enrollment-target?mailingid=30432903&messageid=2900&serial=30432903.2097&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=30432903.2097
Agree Steady_T. Imo this is what a cutting edge biotech company does when it out measures any previous results in real life progress. People taking the drug are getting better. This has never happened in the CNS space. No brain bleeding with real life progress. Minimal to no side effects.
FUD fear, uncertainty and doubt, usually evoked intentionally in order to put a competitor at a disadvantage.
3 Big Reasons to Sell Cassava Sciences Stock Right Now
https://www.yahoo.com/finance/m/e756aec6-fc89-3a6a-a528-43ec4c9f7829/3-big-reasons-to-sell-cassava.html
I agree it's a very positive article. More and more people are learning about Anavex. They will want the drug that works.
Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved
New Efficacy News
The Blarcamesine Phase 2b/3 results are more impressive than the Leqembi Phase 3 results. The cognitive test results clearly favor Blarcamesine.
https://seekingalpha.com/article/4573554-approval-for-anavex-blarcamesine-looks-inevitable?mailingid=30400571&messageid=2800&serial=30400571.2525&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=30400571.2525
georgejjl - Thinking Merck may be a better fit. Thanks
Right and left wings are best left alone. A2-73 is a winner and best in class. Stay focused.
Hard to say when to sell, Kentucky. This could have easily gone to $100.00 and you, me would have kicked ourselves for selling at $28.00. I sleep at night knowing it is the best company in the CNS space. I believe we should have a $5 to $10 billion MC with current drug trial results. GLTU
Perfect..
Xena - You have been one of the biggest contributors of information on this board over the past seven years.
My thanks and Best to you.
B
I don't dought it power. AVXL should have a $5 to $10 billion MC with current drug trial results. imo
samk- Makes a person wonder how many years this has been happening here.
Small-cap companies are going after naked short sellers in growing numbers: ‘It’s the biggest risk to the health of today’s public markets’
https://www.msn.com/en-us/money/companies/small-cap-companies-are-going-after-naked-short-sellers-in-growing-numbers-it-s-the-biggest-risk-to-the-health-of-today-s-public-markets/ar-AA16EueC
Small-cap companies are going after naked short sellers in growing numbers: ‘It’s the biggest risk to the health of today’s public markets’
https://www.msn.com/en-us/money/companies/small-cap-companies-are-going-after-naked-short-sellers-in-growing-numbers-it-s-the-biggest-risk-to-the-health-of-today-s-public-markets/ar-AA16EueC